BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17631646)

  • 21. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.
    Sano D; Kawakami M; Fujita K; Kimura M; Yamashita Y; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
    Oncol Rep; 2007 Feb; 17(2):289-95. PubMed ID: 17203163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
    Troiani T; Lockerbie O; Morrow M; Ciardiello F; Eckhardt SG
    Mol Cancer Ther; 2006 Jul; 5(7):1883-94. PubMed ID: 16891475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
    Damiano V; Melisi D; Bianco C; Raben D; Caputo R; Fontanini G; Bianco R; Ryan A; Bianco AR; De Placido S; Ciardiello F; Tortora G
    Clin Cancer Res; 2005 Aug; 11(15):5639-44. PubMed ID: 16061883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
    Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
    Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
    Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
    BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells.
    Sarkar S; Rajput S; Tripathi AK; Mandal M
    Mol Cancer; 2013 Oct; 12(1):122. PubMed ID: 24138843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
    Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
    Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
    Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
    Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
    Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.
    Ryan AJ; Wedge SR
    Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S6-13. PubMed ID: 15928657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
    Shibuya K; Komaki R; Shintani T; Itasaka S; Ryan A; Jürgensmeier JM; Milas L; Ang K; Herbst RS; O'Reilly MS
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1534-43. PubMed ID: 17889445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo.
    Xiong X; Fu L; Wang L; Cai H; Li L; Jiang H; Duan W; Mei C
    Invest New Drugs; 2009 Feb; 27(1):1-11. PubMed ID: 18493719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Adenovirus-mediated interleukin-24 enhanced the antitumor effect of radiotherapy on nasopharyngeal carcinoma in vitro and in vivo].
    Sun P; Yang JC; Xie YF; Sheng WH; Liu JS
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Nov; 48(11):942-50. PubMed ID: 24444642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells.
    Sarkar S; Mazumdar A; Dash R; Sarkar D; Fisher PB; Mandal M
    J Cell Physiol; 2011 Feb; 226(2):375-84. PubMed ID: 20665703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
    Yang F; Qian XJ; Qin W; Deng R; Wu XQ; Qin J; Feng GK; Zhu XF
    PLoS One; 2013; 8(3):e59879. PubMed ID: 23533654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
    Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
    Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of Src kinase inhibitor ZD6474 on multi-drug resistant K562/A02 cells].
    Jia HY; Li J; Wang ZY; Zhou Q; Wu XM
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):220-4. PubMed ID: 22781612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells.
    Lui VW; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Tsang CM; Lei KI; Chan AT; Mok TS
    Invest New Drugs; 2011 Dec; 29(6):1241-52. PubMed ID: 20571878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of methylation-associated silencing of the death-associated protein kinase gene on nasopharyngeal carcinoma.
    Kong WJ; Zhang S; Guo CK; Wang YJ; Chen X; Zhang SL; Zhang D; Liu Z; Kong W
    Anticancer Drugs; 2006 Mar; 17(3):251-9. PubMed ID: 16520653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.